The effect of oral melatonin before percutaneous nephrolithotomy surgery
Phase 3
Not yet recruiting
- Conditions
- Kidney stones.Calculus of lower urinary tract
- Registration Number
- IRCT20190624043991N26
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 104
Inclusion Criteria
Patients in the age range of 20 to 55 years
Candidate for PCNL surgery under general anesthesia
Written and informed consent from patients
Exclusion Criteria
Neuro-psychiatric diseases such as depression and schizophrenia
Heart diseases and brain treatment
The use of sedatives and beta blockers and sleeping pills or pain relievers
Existence of drug sensitivity
Estimated duration of anesthesia>4 hours
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does melatonin modulate to reduce SIRS and sepsis after PCNL?
How does oral melatonin compare to standard anti-inflammatory agents in preventing post-PCNL complications?
Are there specific urinary tract biomarkers that predict melatonin efficacy in kidney stone patients?
What are the potential adverse events of high-dose melatonin pre-PCNL and optimal dosing strategies?
How do melatonin's antioxidant properties synergize with other nephroprotective agents in urological surgery?